Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.

Publication

Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial.

Journal Paper/Review - Feb 13, 2024

Rech Juergen, Taşçilar Koray, Hagen Melanie, Kleyer Arnd, Manger Bernhard, Schoenau Verena, Hueber Axel J, Kleinert Stefan, Baraliakos Xenofon, Braun Jürgen, Kiltz Uta, Fleck Martin, Rubbert-Roth Andrea, Kofler David M, Behrens Frank, Feuchtenberger Martin, Zaenker Michael, Voll Reinhard E, Venhoff Nils, Thiel Jens, Glaser Cornelia, Feist Eugen, Burmester Gerd R, Karberg Kirsten, Strunk Johannes, Cañete Juan D, Senolt Ladislav, Filkova Maria, Naredo Esperanza, Largo Raquel, Krönke Gerhard, D'Agostino Maria-Antonietta, Østergaard Mikkel, Schett Georg

Citation

Rech J, Taşçilar K, Hagen M, Kleyer A, Manger B, Schoenau V, Hueber A, Kleinert S, Baraliakos X, Braun J, Kiltz U, Fleck M, Rubbert-Roth A, Kofler D, Behrens F, Feuchtenberger M, Zaenker M, Voll R, Venhoff N, Thiel J, Glaser C, Feist E, Burmester G, Karberg K, Strunk J, Cañete J, Senolt L, Filkova M, Naredo E, Largo R, Krönke G, D'Agostino M, Østergaard M, Schett G. Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): a randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet 2024; 403:850-859.

Type

Journal Paper/Review (English)

Journal

Lancet 2024; 403

Publication Date

Feb 13, 2024

Issn Electronic

1474-547X

Pages

850-859

Brief description/objective

Individuals with anti-citrullinated protein antibodies (ACPAs) and subclinical inflammatory changes in joints are at high risk of developing rheumatoid arthritis. Treatment strategies to intercept this pre-stage clinical disease remain to be developed. We aimed to assess whether 6-month treatment with abatacept improves inflammation in preclinical rheumatoid arthritis.